CYP2C9*1B Promoter Polymorphisms, in Linkage with CYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

S.M. de Morais, G. Wilkinson, Joyce Blaisdell et al. · Journal of Biological Chemistry · 1994 · 952 citations · Full text

Medicine, Genetics, Pharmacology +17

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

Theresa H. Sullivan-Klose, Burhan I. Ghanayem, Douglas A. Bell et al. · Pharmacogenetics · 1996 · 587 citations

Medicine, Genetics, Pharmacology +17

CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes

Gang Luo, Mark R. Cunningham, Sean Kim et al. · Drug Metabolism and Disposition · 2002 · 447 citations

Medicine, Pharmacology, Biochemical Pharmacology +15

Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

A. K�pfer, R Preisig · European Journal of Clinical Pharmacology · 1984 · 364 citations

Veterinary Medicine, Genetics, Pharmacology +10

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

Sarah K. Tate, Chantal Depondt, Sanjay M. Sisodiya et al. · Proceedings of the National Academy of Sciences · 2005 · 347 citations

Medicine, Pharmacology, Pharmacotherapy +14